Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 5;10(4):e002944. doi: 10.1136/jitc-2021-002944

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Downstream effects of estrogen receptors (ERs) and regulatory modes of selective estrogen receptor modulators (SERMs)/selective estrogen receptor degraders (SERDs) in prostate cancer (PC). In the top panel, SERM/SERDs which antagonize ERα would reverse resistance, while an agonist of ERβ activity would reverse epithelial-mesenchymal transition (EMT) in PC cells. In the bottom panel, SERMs/SERDs which antagonize ERβ would shift the immunosuppressed tumor immune microenvironment (TIM) to an immune-activated TIM, while an agonist of ERα activity would improve prognosis. VEGFA, vascular endothelial growth factor A.